MA38465A1 - Forme posologique de l'antagoniste du récepteur de la progestérone - Google Patents
Forme posologique de l'antagoniste du récepteur de la progestéroneInfo
- Publication number
- MA38465A1 MA38465A1 MA38465A MA38465A MA38465A1 MA 38465 A1 MA38465 A1 MA 38465A1 MA 38465 A MA38465 A MA 38465A MA 38465 A MA38465 A MA 38465A MA 38465 A1 MA38465 A1 MA 38465A1
- Authority
- MA
- Morocco
- Prior art keywords
- dosage form
- receptor antagonist
- progesterone receptor
- pharmaceutical composition
- relates
- Prior art date
Links
- 229940123788 Progesterone receptor antagonist Drugs 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 2
- 201000010260 leiomyoma Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 201000004458 Myoma Diseases 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002175 menstrual effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- -1 methylsulphonyl Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne une composition pharmaceutique comprenant un antagoniste du récepteur de la progestérone à savoir (11 ß,17ß)-17-hydroxy-11-[4-(méthylsulphonyl)phényle]-17-(pentafluoroéthyl)estra-4,9-dien-3-un dont la posologie est de 0,5 à 5 mg environ et plus particulièrement 2 mg. De plus, l'invention concerne l'utilisation d'une nouvelle composition pharmaceutique destinée au traitement et à la prophylaxie des maladies gynécologiques comme les fibroïdes utérins (myomes, fibrome utérin), l'endométriose ou les saignements menstruels excessifs et un procédé permettant d'obtenir cette composition et une forme posologique orale.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13163417 | 2013-04-11 | ||
| PCT/EP2014/057101 WO2014166971A1 (fr) | 2013-04-11 | 2014-04-09 | Forme posologique de l'antagoniste du récepteur de la progestérone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA38465A1 true MA38465A1 (fr) | 2017-02-28 |
Family
ID=48050601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38465A MA38465A1 (fr) | 2013-04-11 | 2014-04-09 | Forme posologique de l'antagoniste du récepteur de la progestérone |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US20160296534A1 (fr) |
| EP (1) | EP2983671B1 (fr) |
| JP (2) | JP6486900B2 (fr) |
| KR (1) | KR102198059B1 (fr) |
| CN (2) | CN105120873A (fr) |
| AP (1) | AP2015008778A0 (fr) |
| AR (1) | AR095834A1 (fr) |
| AU (1) | AU2014253153B2 (fr) |
| BR (1) | BR112015025706A2 (fr) |
| CA (1) | CA2909121C (fr) |
| CL (1) | CL2015003014A1 (fr) |
| CY (1) | CY1121190T1 (fr) |
| DK (1) | DK2983671T3 (fr) |
| EA (1) | EA032481B1 (fr) |
| ES (1) | ES2708351T3 (fr) |
| HK (1) | HK1218069A1 (fr) |
| HR (1) | HRP20190141T1 (fr) |
| HU (1) | HUE042368T2 (fr) |
| IL (1) | IL241815B (fr) |
| LT (1) | LT2983671T (fr) |
| MA (1) | MA38465A1 (fr) |
| MX (1) | MX363979B (fr) |
| MY (1) | MY188267A (fr) |
| PH (1) | PH12015502326B1 (fr) |
| PL (1) | PL2983671T4 (fr) |
| PT (1) | PT2983671T (fr) |
| RS (1) | RS58277B1 (fr) |
| SG (1) | SG11201507935TA (fr) |
| SI (1) | SI2983671T1 (fr) |
| TN (1) | TN2015000454A1 (fr) |
| TR (1) | TR201900954T4 (fr) |
| TW (2) | TWI672142B (fr) |
| UA (1) | UA116471C2 (fr) |
| WO (1) | WO2014166971A1 (fr) |
| ZA (1) | ZA201801736B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018515551A (ja) * | 2015-05-18 | 2018-06-14 | バイエル・ファルマ・アクティエンゲゼルシャフト | 選択的プロゲステロン受容体モジュレーター（ｓｐｒｍ）レジメン |
| EP3214092A1 (fr) | 2016-03-04 | 2017-09-06 | Bayer Pharma Aktiengesellschaft | Promédicaments du modulateur du récepteur de progesterone (sprm) (11.bêta.,17.bêta.)-17-hydroxy-11-[4-(méthylsulphonyle)phenyle]-17-(pentafluoroéthyl)estra-4,9-dièn-3-one |
| EP3384913A1 (fr) * | 2017-04-03 | 2018-10-10 | Bayer Pharma Aktiengesellschaft | Modulateurs sélectifs du récepteur de la progestérone et niveau d' strogène stabilisé chez un patient |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4426601A1 (de) | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
| DK0792152T3 (da) | 1994-11-22 | 2004-07-12 | Balance Pharmaceuticals Inc | Fremgangsmåder til svangerskabsforebyggelse |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE19706061A1 (de) | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
| AR015500A1 (es) | 1997-12-23 | 2001-05-02 | Schering Ag | 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS. |
| US6476079B1 (en) | 1999-12-23 | 2002-11-05 | Leiras Oy | Devices for the delivery of drugs having antiprogestinic properties |
| DE10159217A1 (de) | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| US8088758B2 (en) * | 2003-11-12 | 2012-01-03 | Abbott Products Gmbh | 17β-hydroxysteroid dehydrogenase type I inhibitors |
| MX2007000273A (es) | 2004-07-09 | 2007-05-21 | Population Council Inc | Composiciones de liberacion sostenida que contiene moduladores del receptor de progesterona. |
| DE102009034362A1 (de) * | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034525A1 (de) * | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102010007722A1 (de) * | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| DE102010007719A1 (de) * | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
-
2014
- 2014-04-09 SI SI201431059T patent/SI2983671T1/sl unknown
- 2014-04-09 MY MYPI2015703556A patent/MY188267A/en unknown
- 2014-04-09 JP JP2016506943A patent/JP6486900B2/ja not_active Expired - Fee Related
- 2014-04-09 CN CN201480020856.3A patent/CN105120873A/zh active Pending
- 2014-04-09 CA CA2909121A patent/CA2909121C/fr active Active
- 2014-04-09 TN TN2015000454A patent/TN2015000454A1/en unknown
- 2014-04-09 WO PCT/EP2014/057101 patent/WO2014166971A1/fr not_active Ceased
- 2014-04-09 PL PL14715933T patent/PL2983671T4/pl unknown
- 2014-04-09 RS RS20190102A patent/RS58277B1/sr unknown
- 2014-04-09 AP AP2015008778A patent/AP2015008778A0/xx unknown
- 2014-04-09 KR KR1020157031928A patent/KR102198059B1/ko not_active Expired - Fee Related
- 2014-04-09 SG SG11201507935TA patent/SG11201507935TA/en unknown
- 2014-04-09 PH PH1/2015/502326A patent/PH12015502326B1/en unknown
- 2014-04-09 LT LTEP14715933.9T patent/LT2983671T/lt unknown
- 2014-04-09 HR HRP20190141TT patent/HRP20190141T1/hr unknown
- 2014-04-09 PT PT14715933T patent/PT2983671T/pt unknown
- 2014-04-09 MX MX2015014264A patent/MX363979B/es active IP Right Grant
- 2014-04-09 HK HK16106042.7A patent/HK1218069A1/zh unknown
- 2014-04-09 EP EP14715933.9A patent/EP2983671B1/fr active Active
- 2014-04-09 ES ES14715933T patent/ES2708351T3/es active Active
- 2014-04-09 CN CN201811621696.4A patent/CN110051619A/zh active Pending
- 2014-04-09 MA MA38465A patent/MA38465A1/fr unknown
- 2014-04-09 UA UAA201510932A patent/UA116471C2/uk unknown
- 2014-04-09 EA EA201501011A patent/EA032481B1/ru active IP Right Revival
- 2014-04-09 US US14/783,839 patent/US20160296534A1/en not_active Abandoned
- 2014-04-09 TR TR2019/00954T patent/TR201900954T4/tr unknown
- 2014-04-09 DK DK14715933.9T patent/DK2983671T3/en active
- 2014-04-09 HU HUE14715933A patent/HUE042368T2/hu unknown
- 2014-04-09 BR BR112015025706A patent/BR112015025706A2/pt not_active IP Right Cessation
- 2014-04-09 AU AU2014253153A patent/AU2014253153B2/en not_active Ceased
- 2014-04-11 TW TW103113485A patent/TWI672142B/zh not_active IP Right Cessation
- 2014-04-11 TW TW107141225A patent/TW201932116A/zh unknown
- 2014-04-11 AR ARP140101553A patent/AR095834A1/es not_active Application Discontinuation
-
2015
- 2015-09-24 IL IL24181515A patent/IL241815B/en active IP Right Grant
- 2015-10-09 CL CL2015003014A patent/CL2015003014A1/es unknown
-
2018
- 2018-03-14 ZA ZA2018/01736A patent/ZA201801736B/en unknown
- 2018-11-09 JP JP2018211340A patent/JP6691193B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-24 CY CY20191100113T patent/CY1121190T1/el unknown
-
2021
- 2021-12-10 US US17/547,720 patent/US20220143045A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121926T1 (el) | (11.βητα., 17.βητα.)-17-υδροξυ-11-[4(μεθυλοσουλφονυλο)φαινυλο]-17-(πενταφθορομεθυλο)οιστρα-4,9-διεν-3-ονη για την αγωγη παθησεων | |
| EA201990835A2 (ru) | Режимы дозирования антипрогестинов | |
| EA201071250A1 (ru) | Композиции и методы для лечения рака молочной железы | |
| CY1114403T1 (el) | Φαρμακευτικη συνθεση, η οποια περιεχει γεσταγονα και/ή οιστρογονα και 5-μεθυλο(6s)-τετραϋδροφολικο | |
| EA201201403A1 (ru) | Очень низкодозированные твердые пероральные лекарственные формы для гзт | |
| NO20062679L (no) | Nye 17 β -hydroksysteroid-dehydrogenase-type 1-inhibitorer | |
| EA200970409A1 (ru) | Композиции и способы, предназначенные для подавления эндометриальной пролиферации | |
| MA38465A1 (fr) | Forme posologique de l'antagoniste du récepteur de la progestérone | |
| MA35867B1 (fr) | Dérivés de la spiroindoline comme antagonistes du récepteur de l'hormone libérant la gonatrophine (gnrh) | |
| WO2009134725A3 (fr) | Compositions et procédés pour traiter des états dépendants de la progestérone | |
| EA201792524A1 (ru) | Режим приема селективного модулятора рецептора прогестерона (sprm) | |
| Mokhtar et al. | Testosterone decreases fluid and chloride secretions in the uterus of adult female rats via down-regulating cystic fibrosis transmembrane regulator (CFTR) expression and functional activity | |
| Thabit et al. | The impact of reproductive hormone changes on the immune response of patients with leukemia | |
| Slonina et al. | Expression of progesterone receptor membrane component 1, serpine mRNA binding protein 1 and nuclear progesterone receptor isoforms A and B in the bovine myometrium during the estrous cycle and early pregnancy | |
| EA201000097A1 (ru) | 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов | |
| Engemise et al. | The effect of the levonorgestrel-releasing intrauterine system, Mirena® on mast cell numbers in women with endometriosis undergoing symptomatic treatment | |
| CY1109919T1 (el) | Παραγωγα της ινδολης που ειναι χρησιμα σα ρυθμιστες του υποδοχεα της προγεστερονης | |
| TW200738665A (en) | Nonsteroidal progesterone receptor modulators | |
| EA200702524A1 (ru) | Нестероидные модуляторы рецептора прогестерона | |
| UA86478U (ru) | Способ лечения синдрома хронической тазовой боли при генитальном эндометриозе | |
| MA38463B1 (fr) | Dérivés de spiroindoline pour une utilisation en tant qu'antagonistes du récepteur de l'hormone de libération des gonadotrophines | |
| TH163150A (th) | รูปแบบยาของโพรเจสเทอโรนรีเซปเตอร์แอนตะกอนิสต์ | |
| Aghajanova et al. | Evidence that eutopic endometrium differs in severe versus mild endometriosis and relevance to fertility |